A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer

Publisher： Karger

E-ISSN： 1421-9794|59|2|106-111

ISSN： 0009-3157

Source： Chemotherapy, Vol.59, Iss.2, 2013-09, pp. : 106-111

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemcitabine plus Cisplatin versus Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Cohort Study

By  

Chemotherapy, Vol. 59, Iss. 3, 2013-12 ,pp. : 232-238

Karger

Access to resources Recommend Favorite

Capecitabine plus Cisplatin as First-Line Chemotherapy for Advanced Biliary Tract Cancer: A Retrospective Single-Center Study

By  

Chemotherapy, Vol. 58, Iss. 3, 2012-07 ,pp. : 225-232

Karger

Access to resources Recommend Favorite

Prospective Phase II Trial of Gemcitabine in Combination with Irinotecan as First-Line Chemotherapy in Patients with Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 57, Iss. 3, 2011-05 ,pp. : 236-243

Karger

Access to resources Recommend Favorite

Prognostic Factors for the Selection of Patients Eligible for Second-Line Chemotherapy in Advanced Biliary Tract Cancer

By  

Chemotherapy, Vol. 60, Iss. 2, 2015-02 ,pp. : 91-98

Karger

Access to resources Recommend Favorite

Phase I/II Trial of Irinotecan and S-1 Combination Chemotherapy as a Second-Line Treatment for Advanced Colorectal Cancer

By  

Chemotherapy, Vol. 59, Iss. 5, 2014-05 ,pp. : 338-343

Karger

Access to resources Recommend Favorite